uniQure (NASDAQ:QURE) Trading 7.2% Higher - Time to Buy?

uniQure (NASDAQ:QURE - Get Free Report)'s stock price was up 7.2% during mid-day trading on Thursday . The company traded as high as $16.16 and last traded at $16.03. Approximately 468,023 shares traded hands during trading, a decline of 75% from the average daily volume of 1,899,432 shares. The stock had previously closed at $14.96.

Wall Street Analyst Weigh In

Several research analysts recently commented on QURE shares. HC Wainwright reaffirmed a "buy" rating and issued a $70.00 target price on shares of uniQure in a research note on Thursday, May 29th. Cantor Fitzgerald raised shares of uniQure to a "strong-buy" rating in a research note on Monday, May 19th. Chardan Capital reissued a "buy" rating and issued a $38.00 target price on shares of uniQure in a research note on Friday, May 30th. Wells Fargo & Company lowered their price target on uniQure from $35.00 to $30.00 and set an "equal weight" rating for the company in a research report on Friday, February 28th. Finally, Wall Street Zen upgraded uniQure from a "sell" rating to a "hold" rating in a research report on Saturday, May 24th. Four analysts have rated the stock with a hold rating, six have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, uniQure currently has a consensus rating of "Moderate Buy" and a consensus target price of $37.82.

uniQure Stock Performance

The company has a 50-day simple moving average of $12.91 and a two-hundred day simple moving average of $13.24. The company has a debt-to-equity ratio of 0.92, a quick ratio of 6.51 and a current ratio of 6.51. The firm has a market capitalization of $945.98 million, a P/E ratio of -3.48 and a beta of 0.08.

uniQure (NASDAQ:QURE - Get Free Report) last posted its quarterly earnings data on Friday, May 9th. The biotechnology company reported ($0.82) earnings per share for the quarter, beating the consensus estimate of ($1.07) by $0.25. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. The business had revenue of $1.57 million for the quarter, compared to analysts' expectations of $5.93 million. As a group, equities analysts forecast that uniQure will post -3.75 EPS for the current year.

Hedge Funds Weigh In On uniQure

Several large investors have recently made changes to their positions in QURE. Palumbo Wealth Management LLC purchased a new position in uniQure during the fourth quarter valued at $437,000. Oppenheimer & Co. Inc. bought a new position in shares of uniQure during the fourth quarter valued at $320,000. Raymond James Financial Inc. purchased a new position in shares of uniQure in the 4th quarter worth about $1,951,000. Monaco Asset Management SAM bought a new position in uniQure in the 4th quarter worth about $2,414,000. Finally, Twin Tree Management LP purchased a new stake in uniQure during the 4th quarter valued at about $77,000. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.